InMed Announces Phase 2 Epidermolysis Bullosa Trial Results; Says 'The results for non-wound itch were not statistically significant in favor of INM-755 CBN cream due, in part, to the clinically important anti-itch effect of the underlying control cream.'
Portfolio Pulse from Bill Haddad
InMed Pharmaceuticals announced Phase 2 trial results for its INM-755 CBN cream, stating that the results for non-wound itch were not statistically significant due to the anti-itch effect of the control cream.
June 22, 2023 | 11:37 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
InMed Pharmaceuticals' INM-755 CBN cream Phase 2 trial results showed no significant improvement in non-wound itch treatment.
The Phase 2 trial results for InMed Pharmaceuticals' INM-755 CBN cream showed no significant improvement in non-wound itch treatment. This may negatively impact the company's stock price as it indicates that the product may not be as effective as initially hoped.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100